 Heritage Investors Management Corp lowered its holdings in shares of  Axon Enterprise, Inc (NASDAQ:AXON – Free Report) by 9.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor  owned 7,193 shares of the biotechnology company’s stock after selling 750 shares during the quarter. Heritage Investors Management Corp’s holdings in Axon Enterprise were worth $5,955,000 at the end of the most recent reporting period.
Heritage Investors Management Corp lowered its holdings in shares of  Axon Enterprise, Inc (NASDAQ:AXON – Free Report) by 9.4% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor  owned 7,193 shares of the biotechnology company’s stock after selling 750 shares during the quarter. Heritage Investors Management Corp’s holdings in Axon Enterprise were worth $5,955,000 at the end of the most recent reporting period. 
Other hedge funds also recently bought and sold shares of the company. TCI Wealth Advisors Inc. purchased a new position in shares of Axon Enterprise in the second quarter valued at approximately $214,000. Duncker Streett & Co. Inc. lifted its position in shares of Axon Enterprise by 3.2% in the second quarter. Duncker Streett & Co. Inc. now owns 14,501 shares of the biotechnology company’s stock valued at $12,006,000 after acquiring an additional 448 shares in the last quarter. Quotient Wealth Partners LLC purchased a new position in shares of Axon Enterprise in the first quarter valued at approximately $438,000. New York Life Investment Management LLC lifted its position in shares of Axon Enterprise by 3.2% in the second quarter. New York Life Investment Management LLC now owns 11,044 shares of the biotechnology company’s stock valued at $9,144,000 after acquiring an additional 341 shares in the last quarter. Finally, DAVENPORT & Co LLC lifted its position in shares of Axon Enterprise by 5.1% in the first quarter. DAVENPORT & Co LLC now owns 940 shares of the biotechnology company’s stock valued at $494,000 after acquiring an additional 46 shares in the last quarter. Hedge funds and other institutional investors own 79.08% of the company’s stock.
Insider Activity at Axon Enterprise
In other Axon Enterprise news, CAO Jennifer H. Mak sold 77 shares of the firm’s stock in a transaction on Monday, September 15th. The stock was sold at an average price of $760.00, for a total transaction of $58,520.00. Following the completion of the sale, the chief accounting officer owned 15,003 shares of the company’s stock, valued at $11,402,280. This trade represents a 0.51% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Brittany Bagley sold 5,000 shares of the firm’s stock in a transaction on Monday, September 29th. The stock was sold at an average price of $713.88, for a total value of $3,569,400.00. Following the sale, the chief financial officer directly owned 93,592 shares of the company’s stock, valued at approximately $66,813,456.96. This trade represents a 5.07% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 59,932 shares of company stock valued at $45,115,616 over the last 90 days. Corporate insiders own 4.40% of the company’s stock.
Analyst Ratings Changes
View Our Latest Research Report on Axon Enterprise
Axon Enterprise Price Performance
AXON stock opened at $759.44 on Thursday. The business has a fifty day moving average of $732.23 and a two-hundred day moving average of $730.52. The company has a quick ratio of 2.71, a current ratio of 2.95 and a debt-to-equity ratio of 0.63. The stock has a market cap of $59.62 billion, a price-to-earnings ratio of 187.52, a price-to-earnings-growth ratio of 29.32 and a beta of 1.41. Axon Enterprise, Inc has a 52-week low of $422.38 and a 52-week high of $885.91.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its earnings results on Monday, August 4th. The biotechnology company reported $2.12 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.54 by $0.58. The company had revenue of $668.54 million during the quarter, compared to analysts’ expectations of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.The firm’s quarterly revenue was up 32.6% compared to the same quarter last year. During the same quarter last year, the firm earned $1.20 earnings per share. Axon Enterprise has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.
Axon Enterprise Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Featured Stories
- Five stocks we like better than Axon Enterprise
- What Does Downgrade Mean in Investing?
- After Q3 Beat, Chip Giant Cadence Eyes AI’s Horizon 2: Robots
- What is the Nasdaq? Complete Overview with History
- These 3 High-Momentum ETFs Are Riding the Tech Wave
- What is diluted earnings per share (Diluted EPS)?
- Verizon Results Trigger Rebound in High-Yield Stock
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.

 
						 
						 
						 
						 
						